← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,321	+92	+4%	$207B
2	2 Pfizer PFE $166B	2,059	+95	+5%	$140B
3	3 Merck MRK $364B	1,912	+97	+5%	$120B
4	4 AbbVie ABBV $501B	1,692	+38	+2%	$68.3B
5	5 Bristol-Myers Squibb BMY $121B	1,601	+78	+5%	$69.3B
6	6 Gilead Sciences GILD $190B	1,574	+13	+0.8%	$71.2B
7	7 Amgen AMGN $230B	1,541	+23	+2%	$84.9B
8	8 Novartis NVS $279B	905	+28	+3%	$18.2B
9	9 GSK GSK $95.9B	763	+21	+3%	$8.05B
10	10 Regeneron Pharmaceuticals REGN $80.1B	576	+21	+4%	$26.3B
11	11 AstraZeneca AZN $251B	450	-1	-0.2%	$8.63B
12	12 Incyte INCY $22.6B	432	+33	+8%	$17.4B
13	13 Jazz Pharmaceuticals JAZZ $13.6B	296	-31	-9%	$5.68B
14	SGEN 14 DELISTED Seagen Inc. Common Stock SGEN	270	+28	+12%	$7.29B
15	15 Opko Health OPK $1.02B	256	-14	-5%	$1.24B
16	16 Exelixis EXEL $15.1B	228	+24	+12%	$3.54B
17	17 DELISTED Exact Sciences EXAS	223	-2	-0.9%	$1.3B
18	18 Myriad Genetics MYGN $397M	223	-1	-0.4%	$1.35B
19	19 DELISTED Assertio ASRT	204	0	0%	$1.11B
20	20 Precigen PGEN $2.64B	171	+2	+1%	$2.42B
21	21 Halozyme HALO $13.3B	168	+6	+4%	$1.09B
22	CLVS 22 DELISTED Clovis Oncology, Inc. CLVS	167	+4	+2%	$1.68B
23	23 DELISTED Radius Health, Inc. RDUS	157	-14	-8%	$1.64B
24	24 DELISTED Immunogen Inc IMGN	156	0	0%	$137M
25	25 DELISTED Eagle Pharmaceuticals, Inc. EGRX	149	+12	+9%	$1.31B